Atossa Therapeutics’ (ATOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report published on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock.

ATOS has been the subject of several other reports. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Trading Down 3.5 %

ATOS opened at $1.11 on Thursday. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.33. Atossa Therapeutics has a 12-month low of $0.70 and a 12-month high of $2.31.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ATOS. Bank of New York Mellon Corp boosted its stake in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after purchasing an additional 164,540 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics during the second quarter valued at $161,000. Barclays PLC increased its holdings in Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after buying an additional 123,683 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.